Global / Top Biologics CDMOs 2023
Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs…
Patrick is the managing editor of PharmaBoardroom, writing and editing stories on all things healthcare and the life sciences. The holder of a Master's Degree in International Relations, Patrick has contributed to over 40 country reports and is a fluent Mandarin speaker.
Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs…
The latest news from Spanish pharmaceuticals and healthcare, including national champion Esteve’s decision to sell of a quarter of its stock to German private investment firm Lubea; news of pharma’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
Well established as Asia’s leading financial services and trading hub, Hong Kong is now looking to better position itself as a centre for biotechnology investment and start-ups. However, in a…
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the…
Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59,…
Country managers from three leading medtech multinationals give their take on the key access challenges facing medical device companies in Greece. New Access Models “While some value-based procurement agreements…
One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of…
See our Cookie Privacy Policy Here